Results 161 to 170 of about 206,755 (278)
A quasi-experimental study evaluating the efficacy of crossmatch-matched platelet transfusions in hemato-oncology patients with suspected alloimmune platelet refractoriness: A single-centre experience. [PDF]
Transfus MedKaur D +7 more
europepmc +1 more source
Platelet demand is unpredictable and will relate to case mix, programmes of treatment requiring intensive platelet support and health service activity.
Samantha J. Reynolds (24033552)
core +1 more source
A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial
British Journal of Haematology, EarlyView.The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne +28 more
wiley +1 more source
British Journal of Haematology, EarlyView.High versus low baseline CAR‐HEMATOTOX scores were associated with poorer safety and efficacy outcomes in patients with R/R B‐NHL who received odronextamab in the ELM‐1 and ELM‐2 studies. The CAR‐HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.
Matthew Matasar +9 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Successful surgical procedure in a patient of aplastic anemia with platelet refractoriness, using cross-match compatible platelets. [PDF]
Asian J Transfus Sci, 2017 Chakrabarty R, Das SS.
europepmc +1 more source
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes +7 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher +6 more
wiley +1 more source
POLA2‐Related Coats Plus Syndrome: Case Presentation and Description of an Emerging Disorder
Clinical Genetics, EarlyView.We report an adult male with bilateral retinal vascular disease, hypocellular bone marrow failure, severe gastrointestinal bleeding, and premature hair graying, with telomere lengths near the 10th percentile. Exome sequencing resulted in the diagnosis of POLA2‐related Coats plus syndrome, making him the sixth reported case.
Daniel W. Serber +7 more
wiley +1 more source